Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...

SOUTH SAN FRANCISCO, CA, USA I 06, 2025 I Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% ...

Announcement coincides with WORLDSymposium™ presentation highlighting knockdown of GYS1 mRNA and protein in muscle, as well as favorable safety and ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – ...

SHANGHAI, China I 5, 2025 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as ...

CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SHANGHAI, China I 4, 2025 I Harbour BioMed (HKEX: 02142, the "Company"), a global ...

CHICAGO, IL, USA I 04, 2025 I COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies ...

BOSTON, MA, USA and LAUSANNE, Switzerland I 4, 2025 I Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces ...

Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 ...

DÜSSELDORF, Germany I 04, 2025 I Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic ...